SCHEDULE 13D/A

LARIMAR THERAPEUTICS INC

Common Stock, par value $0.0001 per share · CUSIP: 517125100

Event date: 2025-07-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares

Unavailable

Percent of class

Unavailable

• Deerfield Private Design Fund III, L.P.Reported CIK 0001603333

  Shares: 9,538,918.00 · Class: 11.14%

• Deerfield Healthcare Innovations Fund, L.P.Reported CIK 0001646981

  Shares: 7,321,129.00 · Class: 8.55%

• Deerfield Private Design Fund IV, L.P.Reported CIK 0001680307

  Shares: 9,538,945.00 · Class: 11.14%

• Deerfield Partners, L.P.Reported CIK 0001301041

  Shares: 4,207,982.00 · Class: 4.91%

• Deerfield Mgmt III, L.P.Reported CIK 0001610540

  Shares: 9,538,918.00 · Class: 11.14%

• Deerfield Mgmt HIF, L.P.Reported CIK 0001665736

  Shares: 7,321,129.00 · Class: 8.55%

• Deerfield Mgmt IV, L.P.Reported CIK 0001713467

  Shares: 9,538,945.00 · Class: 11.14%

• Deerfield Mgmt, L.P.Reported CIK 0001010823

  Shares: 4,207,982.00 · Class: 4.91%

• Deerfield Management Company, L.P.Reported CIK 0001009258

  Shares: 30,667,474.00 · Class: 35.81%

• James E. FlynnReported CIK 0001352546

  Shares: 30,667,474.00 · Class: 35.81%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.